Clayton Falknor, MD
Cornea and External Diseases Specialist · Colorado Springs, CONPI 1164625018
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Alcon at 30.1% of the total. Reporting peaked in 2023 at $272 and has fallen 85.1% since, to $41 in 2025.
Across 28 payments — averaging $35.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$303
- Rxsight Inc$269
- Aerie Pharmaceuticals, Inc.$124
- Dompe US, Inc.$121
- NEW World Medical,inc.$74
- Glaukos Corporation$38
- plus $77 from 3 others
What the payments were for
- Food & beverage$1,006100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 14 | $303 |
| Rxsight Inc | 4 | $269 |
| Aerie Pharmaceuticals, Inc. | 1 | $124 |
| Dompe US, Inc. | 1 | $121 |
| NEW World Medical,inc. | 1 | $74 |
| Glaukos Corporation | 2 | $38 |
| Biotissue Holdings Inc. | 2 | $33 |
| Sun Pharmaceutical Industries Inc. | 2 | $31 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few cornea and external diseases specialist providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 12 | $11,874 |
| Fluorometholone | 138 | $10,518 |
| Prednisolone Acetate | 292 | $9,772 |
| Ketorolac Tromethamine | 98 | $4,389 |
| Latanoprost | 283 | $3,667 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 108 | $1,810 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $1,305 |
| ValacyclovirValacyclovir Hcl | 21 | $1,249 |
| MoxifloxacinMoxifloxacin Hcl | 46 | $1,189 |
| Timolol Maleate | 103 | $1,184 |
| Brimonidine Tartrate | 46 | $470 |
| Dorzolamide Hcl | 16 | $431 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 23 | $367 |
| Ofloxacin | 24 | $302 |
| ErythromycinErythromycin Base | 23 | $294 |
Paid to pharmacies, not to this prescriber.
Other cornea and external diseases specialist in Colorado Springs
- James SbarbaroColorado Springs$1K
- Nitin ChopraColorado Springs$432
- Michael TaravellaAurora$12K
- Karen ChristopherAurora$3K
- Aimee VernerLongmont$3K
- Christopher GelstonAurora$2K
- Christopher HamptonWheat Ridge$1K
- Ronald WiseDenver$1K
- Michael WildesAurora$1K
- Brittany PerziaAurora$956
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.